Drug Profile
INV 103
Alternative Names: ala-chaperonin-10; Ala-Cpn10; Chaperonin 10; Cpn 10; Heat shock protein 10 - Invion; HSP-10 - Invion; INV103; Recombinant Cpn 10; XTollLatest Information Update: 09 Aug 2019
Price :
$50
*
At a glance
- Originator CBio
- Developer Invion
- Class Anti-inflammatories; Antirheumatics; Chaperonins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- No development reported Multiple sclerosis; Plaque psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Ulcerative colitis
Most Recent Events
- 09 Aug 2019 No development reported - Phase-I/II for Systemic lupus erythematosus in USA (IV)
- 09 Aug 2019 No development reported - Phase-II for Ulcerative colitis in Australia (IV)
- 14 Nov 2014 HSP 10 is available for licensing as of 14 Nov 2014. http://inviongroup.com